{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:55:01Z","timestamp":1778540101443,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.leukres.2022.106840","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T01:49:22Z","timestamp":1649728162000},"page":"106840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["CD5-positive marginal zone lymphoma: Clinicopathological features and survival outcomes"],"prefix":"10.1016","volume":"117","author":[{"given":"Yaqin","family":"Xia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurui","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenchang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feifei","family":"Nan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaorui","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2022.106840_bib1","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin\u2019s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin\u2019s Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2022.106840_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1046\/j.1365-2559.2002.01360.x","article-title":"Marginal zone cell lymphoma--an update on recent advances","volume":"40","author":"Maes","year":"2002","journal-title":"Histopathology"},{"key":"10.1016\/j.leukres.2022.106840_bib3","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106840_bib4","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","article-title":"Splenic marginal zone lymphoma: from genetics to management","volume":"127","author":"Arcaini","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106840_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Zucca","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2022.106840_bib6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2147\/CMAR.S133291","article-title":"Management of relapsed\/refractory marginal zone lymphoma: focus on ibrutinib","volume":"10","author":"Denlinger","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.leukres.2022.106840_bib7","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.3324\/haematol.2019.237990","article-title":"Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment","volume":"105","author":"Conconi","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2022.106840_bib8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.autrev.2008.11.007","article-title":"CD5: a safeguard against autoimmunity and a shield for cancer cells","volume":"8","author":"Dalloul","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.leukres.2022.106840_bib9","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s12288-014-0332-1","article-title":"Aberrant immunophenotypic expression of CD5 in a Case of B acute lymphoblastic leukemia: a case report","volume":"30","author":"Mutreja","year":"2014","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"10.1016\/j.leukres.2022.106840_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ajcp\/105.1.31","article-title":"CD5+ extranodal marginal zone B-cell (MALT) lymphoma. A low grade neoplasm with a propensity for bone marrow involvement and relapse","volume":"105","author":"Ferry","year":"1996","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.leukres.2022.106840_bib11","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3109\/10428190109099348","article-title":"CD5 expression in a lymphoma of the mucosa-associated lymphoid tissue (MALT)-type as a marker for early dissemination and aggressive clinical behaviour","volume":"42","author":"Wenzel","year":"2001","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2022.106840_bib12","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","article-title":"A MALT lymphoma prognostic index","volume":"130","author":"Thieblemont","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106840_bib13","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106840_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3960\/jslrt.54.3","article-title":"Pathology of follicular lymphoma","volume":"54","author":"Takata","year":"2014","journal-title":"J. Clin. Exp. Hematopathol."},{"key":"10.1016\/j.leukres.2022.106840_bib15","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/annonc\/mdv368","article-title":"Histologic transformation in marginal zone lymphomas\u2020","volume":"26","author":"Conconi","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2022.106840_bib16","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.4049\/jimmunol.123.3.1312","article-title":"A monoclonal antibody with selective reactivity with functionally mature human thymocytes and all peripheral human T cells","volume":"123","author":"Reinherz","year":"1979","journal-title":"J. Immunol."},{"key":"10.1016\/j.leukres.2022.106840_bib17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1084\/jem.152.1.229","article-title":"An antigen shared by a human T cell subset and B cell chronic lymphocytic leukemic cells. Distribution on normal and malignant lymphoid cells","volume":"152","author":"Boumsell","year":"1980","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.leukres.2022.106840_bib18","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.autrev.2012.02.007","article-title":"CD5 expression promotes multiple intracellular signaling pathways in B lymphocyte","volume":"11","author":"Mageed","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.leukres.2022.106840_bib19","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/cmi.2016.42","article-title":"CD5 expression promotes IL-10 production through activation of the MAPK\/Erk pathway and upregulation of TRPC1 channels in B lymphocytes","volume":"15","author":"Garaud","year":"2018","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.leukres.2022.106840_bib20","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.18632\/oncotarget.3479","article-title":"Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries","volume":"6","author":"Xu-Monette","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2022.106840_bib21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41375-018-0303-x","article-title":"The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia","volume":"33","author":"Ten Hacken","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2022.106840_bib22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/jcp.2009.067603","article-title":"Correlation of autoantibodies and CD5+ B cells in ocular adnexal marginal zone B cell lymphomas","volume":"63","author":"Kubota","year":"2010","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.leukres.2022.106840_bib23","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1053\/S0046-8177(03)00400-3","article-title":"Cytogenetic evidence for the origin of neoplastic cells in CD5-positive marginal zone B-cell lymphoma","volume":"34","author":"Batstone","year":"2003","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.leukres.2022.106840_bib24","first-page":"311","article-title":"Primary hepatic marginal zone B-cell lymphoma with mantle cell lymphoma phenotype","volume":"428","author":"Ueda","year":"1996","journal-title":"Virchows Arch."},{"key":"10.1016\/j.leukres.2022.106840_bib25","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1136\/bjo.85.4.496c","article-title":"Conjunctival CD5+ MALT lymphoma","volume":"85","author":"Heuring","year":"2001","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.leukres.2022.106840_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1440-1827.2006.02063.x","article-title":"CD5-positive mucosa-associated lymphoid tissue (MALT) lymphoma of ocular adnexal origin: usefulness of fluorescence in situ hybridization for distinction between mantle cell lymphoma and MALT lymphoma","volume":"57","author":"Tasaki","year":"2007","journal-title":"Pathol. Int."},{"key":"10.1016\/j.leukres.2022.106840_bib27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00000478-199802000-00008","article-title":"CD5+ low-grade marginal zone B-cell lymphomas with localized presentation","volume":"22","author":"Ballesteros","year":"1998","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.leukres.2022.106840_bib28","doi-asserted-by":"crossref","first-page":"800138","DOI":"10.1200\/JCO.18.00138","article-title":"Risk factors for transformation to higher-grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution","volume":"36","author":"Alderuccio","year":"2018","journal-title":"J. Clin. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622000662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622000662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:02:26Z","timestamp":1758934946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212622000662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":28,"alternative-id":["S0145212622000662"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106840","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-948719\/v1","asserted-by":"object"}]},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD5-positive marginal zone lymphoma: Clinicopathological features and survival outcomes","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106840","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106840"}}